Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy.

about

Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy.

Item

http://www.wikidata.org/entity/Q42256057

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Local prostate cancer radiothe ...... ring primary hormonal therapy.

@en

Local prostate cancer radiothe ...... ring primary hormonal therapy.

@nl

type

Item

label

Local prostate cancer radiothe ...... ring primary hormonal therapy.

@en

Local prostate cancer radiothe ...... ring primary hormonal therapy.

@nl

prefLabel

Local prostate cancer radiothe ...... ring primary hormonal therapy.

@en

Local prostate cancer radiothe ...... ring primary hormonal therapy.

@nl

P1476

Local prostate cancer radiothe ...... ring primary hormonal therapy.

@en

P2093

Axel Heidenreich

http://www.w3.org/2001/XMLSchema#string

David Pfister

http://www.w3.org/2001/XMLSchema#string

Jens Klotz

http://www.w3.org/2001/XMLSchema#string

Marc D Piroth

http://www.w3.org/2001/XMLSchema#string

Michael J Eble

http://www.w3.org/2001/XMLSchema#string

Michael Pinkawa

http://www.w3.org/2001/XMLSchema#string

Richard Holy

http://www.w3.org/2001/XMLSchema#string

Victoria Djukic

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials.

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer

Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31.

External beam radiotherapy for prostate cancer.

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy.

P2888

1748-717x-7-209

P304

209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1748-717X-7-209

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1014582303

http://www.w3.org/2001/XMLSchema#string

P698

23227960

http://www.w3.org/2001/XMLSchema#string

P932

3551819

http://www.w3.org/2001/XMLSchema#string